I am a
Home I AM A Search Login

Papers of the Week

Papers: 27 Aug 2022 - 2 Sep 2022

Pharmacology/Drug Development

2022 Sep 01

Cochrane Database Syst Rev


Hydroxyurea (hydroxycarbamide) for sickle cell disease.


Rankine-Mullings AE, Nevitt SJ
Cochrane Database Syst Rev. 2022 Sep 01; 9:CD002202.
PMID: 36047926.


Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. It is associated with lifelong morbidity and a reduced life expectancy. Hydroxyurea (hydroxycarbamide), an oral chemotherapeutic drug, ameliorates some of the clinical problems of SCD, in particular that of pain, by raising foetal haemoglobin (HbF). This is an update of a previously published Cochrane Review.